Egetis’ Q4 report presented SEK32.6m in revenues, of which SEK14.5m was a milestone payment related to the licensing deal with Fujimoto, and SEK-115.7m in operating expenses, indicating high activities related to clinical study and commercial preparation. The company’s cash position amounted to SEK303m, and the company has access to an additional EUR15m in loans available when the company reaches certain milestones. Egetis mentions in the report that it has recruited two new hospitals for the ReTRIACt study and that 10 patients had been included in the study, but gives no new timeline (will be announced once the trial is fully recruited). We will soon return with a more extensive take but don’t expect to make any significant changes.